171 related articles for article (PubMed ID: 37003022)
1. Functionalisation of extracellular vesicles with cyclic-RGDyC potentially for glioblastoma targeted intracellular drug delivery.
Geng T; Leung E; Chamley LW; Wu Z
Biomater Adv; 2023 Jun; 149():213388. PubMed ID: 37003022
[TBL] [Abstract][Full Text] [Related]
2. A simple approach to re-engineering small extracellular vesicles to circumvent endosome entrapment.
Geng T; Tang M; Yee Paek S; Leung E; Chamley LW; Wu Z
Int J Pharm; 2022 Oct; 626():122153. PubMed ID: 36055444
[TBL] [Abstract][Full Text] [Related]
3. Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An in vitro boron neutron capture therapy study.
Kang W; Svirskis D; Sarojini V; McGregor AL; Bevitt J; Wu Z
Oncotarget; 2017 May; 8(22):36614-36627. PubMed ID: 28402271
[TBL] [Abstract][Full Text] [Related]
4. Eliminating the original cargos of glioblastoma cell-derived small extracellular vesicles for efficient drug delivery to glioblastoma with improved biosafety.
Guo Y; Hu G; Xia Y; Li H; Yuan J; Zhang J; Chen Y; Guo H; Yang Y; Wang Y; Deng Z
Bioact Mater; 2022 Oct; 16():204-217. PubMed ID: 35386327
[TBL] [Abstract][Full Text] [Related]
5. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
6. Development of Functional Chimeric Nanoparticles by Membrane Fusion of Small Extracellular Vesicles and Drug-Encapsulated Liposomes.
Fukuta T; Nishikawa A; Hiramachi A; Yamashita S; Kogure K
Biol Pharm Bull; 2023; 46(8):1098-1104. PubMed ID: 37532560
[TBL] [Abstract][Full Text] [Related]
7. Cyclo(RGD)-Decorated Reduction-Responsive Nanogels Mediate Targeted Chemotherapy of Integrin Overexpressing Human Glioblastoma In Vivo.
Chen W; Zou Y; Zhong Z; Haag R
Small; 2017 Feb; 13(6):. PubMed ID: 27865044
[TBL] [Abstract][Full Text] [Related]
8. Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles.
Zottel A; Šamec N; Kump A; Raspor Dall'Olio LR; Pužar Dominkuš P; Romih R; Hudoklin S; Mlakar J; Nikitin D; Sorokin M; Buzdin A; Jovčevska I; Komel R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187334
[TBL] [Abstract][Full Text] [Related]
9. Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner.
Whitehead CA; Fang H; Su H; Morokoff AP; Kaye AH; Hanssen E; Nowell CJ; Drummond KJ; Greening DW; Vella LJ; Mantamadiotis T; Stylli SS
Cell Oncol (Dordr); 2023 Aug; 46(4):909-931. PubMed ID: 37014551
[TBL] [Abstract][Full Text] [Related]
10. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma.
Dragojevic S; Mackey R; Raucher D
Molecules; 2019 Sep; 24(18):. PubMed ID: 31489879
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the Design of Blood-Brain Barrier-Penetrating Polymer-Lipid-Hybrid Nanoparticles for Delivering Anticancer Drugs to Glioblastoma.
Ahmed T; Liu FF; He C; Abbasi AZ; Cai P; Rauth AM; Henderson JT; Wu XY
Pharm Res; 2021 Nov; 38(11):1897-1914. PubMed ID: 34655006
[TBL] [Abstract][Full Text] [Related]
14. Separation of U87 glioblastoma cell-derived small and medium extracellular vesicles using elasto-inertial flow focusing (a spiral channel).
Shiri F; Feng H; Petersen KE; Sant H; Bardi GT; Schroeder LA; Merchant ML; Gale BK; Hood JL
Sci Rep; 2022 Apr; 12(1):6146. PubMed ID: 35414673
[TBL] [Abstract][Full Text] [Related]
15. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Protect Cardiomyocytes from Doxorubicin-Induced Cardiomyopathy by Upregulating Survivin Expression via the miR-199a-3p-Akt-Sp1/p53 Signaling Pathway.
Lee JY; Chung J; Byun Y; Kim KH; An SH; Kwon K
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281156
[TBL] [Abstract][Full Text] [Related]
18. Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping.
Lane R; Simon T; Vintu M; Solkin B; Koch B; Stewart N; Benstead-Hume G; Pearl FMG; Critchley G; Stebbing J; Giamas G
Commun Biol; 2019; 2():315. PubMed ID: 31453379
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
20. LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells.
Wu P; Guo Y; Xiao L; Yuan J; Tang C; Dong J; Qian Z
Cancer Immunol Immunother; 2023 Jul; 72(7):2179-2193. PubMed ID: 36853330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
